Folic acid conjugated nanoliposomes as promising carriers for targeted delivery of bleomycin. (19th May 2018)

• Record Type: Journal Article
• Authors: Chiani, Mohsen; Norouzian, Dariush; Shokrgozar, Mohammad Ali; Azadmanesh, Kayhan; Najmafshar, Aazam; Mehrabi, Mohammad Reza; Akbarzadeh, Azim
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 46:Number 4(2018)
• Page Start: 757
• Page End: 763
• Publication Date: 2018-05-19
• Subjects: Bleomycin -- targeted drug delivery -- nanoliposomes -- cytotoxicity -- uptake -- apoptosis; Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.1080/21691401.2017.1337029
• Languages: English
• ISSNs: 2169-1401

Abstract

Abstract: Targeted drug delivery has received considerable attention due to its key role in improving therapeutic efficacy and reducing the side effects of anticancer drugs. Bleomycin (BLM) is an anticancer antibiotic with short half-life, low therapeutic and high side effects that limit its clinical applications. This study aims to evaluate the anticancer potential of folate-targeted liposomal bleomycin (FL-BLM) and its free-folate form (L-BLM) on two different cancer cell lines including human cervix carcinoma HeLa, and human breast carcinoma MCF-7 cells. Furthermore, the effect of FL-BLM in induction of apoptosis and cell cycle arrest was studied by flow cytometry. FL-BLM was prepared by thin film hydration method and folic acid was conjugated to nanoliposomes by post insertion technique. Anticancer activity was evaluated by MTT assay. The cytotoxicity of FL-BLM against HeLa cells was significantly increased compared to L-BLM and conventional BLM. Flow cytometry and annexin-V analysis indicated that FL-BLM effectively induced apoptosis and cell-cycle arrest in HeLa cells especially at G2/M phase. In addition, the uptake of FL-BLM by Hela cells was significantly increased as compared to the MCF-7 cells. Overall, our findings indicated that FL-BLM may be promising formulation for targeted drug delivery to folate receptor-positive tumour cells.